经导管三尖瓣修复系统治疗重度三尖瓣反流的6个月结局
TRI-REPAIR单臂多中心前瞻性研究纳入30例中重度功能性三尖瓣反流患者,评估经导管三尖瓣修复系统的6个月安全性和性能。技术成功率100%,6个月内3例死亡;超声显示瓣环前后径、有效反流口面积和缩流颈宽度显著减小,76%患者NYHA心功能改善至少1级,6分钟步行距离和生活质量评分显著提高。
要点
- 经导管三尖瓣修复系统技术成功率100%,6个月死亡率10%(3/30)。
- 6个月时有效反流口面积从0.8 cm²降至0.4 cm²(p<0.01),缩流颈宽度从1.2 cm降至0.9 cm。
- 76%患者NYHA心功能改善至少1级,6分钟步行距离提高60米,KCCQ评分提高24分。
核心结论
- 经导管三尖瓣修复系统在6个月时表现符合预期,在症状性中重度功能性三尖瓣反流患者中似乎安全,并观察到三尖瓣反流显著减少及心衰症状、生活质量和运动能力改善。
研究设计与样本
- TRI-REPAIR研究为单臂、多中心、前瞻性试验,2016年10月至2017年7月共纳入30例中重度症状性功能性三尖瓣反流患者,因开胸手术风险不可接受而判定为不可手术。
- 前瞻性收集术前及术后6个月内的临床、功能和超声心动图数据,超声数据由独立核心实验室评估,安全事件由独立临床事件委员会裁定。
主要发现
- 患者平均年龄75岁,73%为女性,23%有缺血性心脏病;基线时83%为NYHA心功能III-IV级,平均左心室射血分数58%。
- 技术成功率为100%;至6个月时3例患者死亡。
- 6个月与基线相比,瓣环前后径平均缩小9%(42 mm vs. 38 mm;p<0.01),近端等速表面积有效反流口面积平均缩小50%(0.8 cm² vs. 0.4 cm²;p<0.01),平均缩流颈宽度缩小28%(1.2 cm vs. 0.9 cm;p<0.01)。
- 76%患者NYHA心功能改善至少1级,88%患者达到NYHA心功能I或II级;6分钟步行距离提高60米(p<0.01),堪萨斯城心肌病问卷评分提高24分(p<0.01)。
临床怎么用
- 对于因外科手术风险不可接受而判定为不可手术的症状性中重度功能性三尖瓣反流患者,经导管三尖瓣修复系统可能作为改善心衰症状、生活质量和运动能力的治疗选择。
- 术后6个月内需关注死亡风险,本研究6个月内3例患者死亡。
局限性
- 本研究为单臂、非对照、样本量30例的试验,结果需进一步研究验证。
- 随访时间仅6个月,长期安全性和有效性尚未确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Severe tricuspid regurgitation (TR) is associated with high morbidity and mortality rates with limited treatment options. OBJECTIVES: The authors report the 6-month safety and performance of a transcatheter tricuspid valve reconstruction system in the treatment of moderate to severe functional TR in 30 patients enrolled in the TRI-REPAIR (TrIcuspid Regurgitation RePAIr With CaRdioband Transcatheter System) study. METHODS: Between October 2016 and July 2017, 30 patients were enrolled in this single-arm, multicenter, prospective trial. Patients were diagnosed with moderate to severe, symptomatic TR in the absence of untreated left-heart disease and deemed inoperable because of unacceptable risk for open-heart surgery by the local heart team. Clinical, functional, and echocardiographic data were prospectively collected before and up to 6 months post-procedure. An independent core lab assessed all echocardiographic data, and an independent clinical event committee adjudicated the safety events. RESULTS: Mean patient age was 75 years, 73% were female, and 23% had ischemic heart disease. At baseline, 83% were in New York Heart Association (NYHA) functional class III to IV, and mean left ventricular ejection fraction was 58%. Technical success was 100%. Through 6 months, 3 patients died. Between 6 months and baseline, echocardiography showed average reductions of annular septolateral diameter of 9% (42 mm vs. 38 mm; p < 0.01), proximal isovelocity surface area effective regurgitant orifice area of 50% (0.8 cm2 vs. 0.4 cm2; p < 0.01), and mean vena contracta width of 28% (1.2 cm vs. 0.9 cm; p < 0.01). Clinical assessment showed that 76% of patients improved by at least 1 NYHA functional class with 88% in NYHA functional class I or II. Six-minute walk distance improved by 60 m (p < 0.01), and Kansas City Cardiomyopathy Questionnaire score improved by 24 points (p < 0.01). CONCLUSIONS: Six-month outcomes show that the system performs as intended and appears to be safe in patients with symptomatic and moderate to severe functional TR. Significant reduction of TR through decrease of annular dimensions, improvements in heart failure symptoms, quality of life, and exercise capacity were observed. Further studies are warranted to validate these initial promising results. (TrIcuspid Regurgitation RePAIr With CaRdioband Transcatheter System [TRI-REPAIR]; NCT02981953).
引用
- Nickenig G, Weber M, Schueler R, et al. 6-Month Outcomes of Tricuspid Valve Reconstruction for Patients With Severe Tricuspid Regurgitation. J Am Coll Cardiol. 2019. PMID: 30999993. doi:10.1016/j.jacc.2019.01.062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。